{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:00:54Z","timestamp":1791460854232,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2016M600455"],"award-info":[{"award-number":["2016M600455"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2017T100423"],"award-info":[{"award-number":["2017T100423"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011360","name":"State Key Laboratory of Natural Medicines","doi-asserted-by":"publisher","award":["SKLNMZZCX201610"],"award-info":[{"award-number":["SKLNMZZCX201610"]}],"id":[{"id":"10.13039\/501100011360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011360","name":"State Key Laboratory of Natural Medicines","doi-asserted-by":"publisher","award":["SKLNMZZCX201801"],"award-info":[{"award-number":["SKLNMZZCX201801"]}],"id":[{"id":"10.13039\/501100011360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013313","name":"Overseas Expertise Introduction Project for Discipline Innovation","doi-asserted-by":"publisher","award":["CPU2018GF01"],"award-info":[{"award-number":["CPU2018GF01"]}],"id":[{"id":"10.13039\/501100013313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013313","name":"Overseas Expertise Introduction Project for Discipline Innovation","doi-asserted-by":"publisher","award":["CPU2018GF09"],"award-info":[{"award-number":["CPU2018GF09"]}],"id":[{"id":"10.13039\/501100013313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013313","name":"Overseas Expertise Introduction Project for Discipline Innovation","doi-asserted-by":"publisher","award":["G20582017001"],"award-info":[{"award-number":["G20582017001"]}],"id":[{"id":"10.13039\/501100013313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81421005"],"award-info":[{"award-number":["81421005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81430091"],"award-info":[{"award-number":["81430091"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81603194"],"award-info":[{"award-number":["81603194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81720108032"],"award-info":[{"award-number":["81720108032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91429308"],"award-info":[{"award-number":["91429308"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.apsb.2018.11.004","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T01:34:04Z","timestamp":1543282444000},"page":"526-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis"],"prefix":"10.1016","volume":"9","author":[{"given":"Jiyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoliang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2018.11.004_bib1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.apsb.2016.07.015","article-title":"Role of farnesoid X receptor in establishment of ontogeny of phase-I drug metabolizing enzyme genes in mouse liver","volume":"6","author":"Peng","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2018.11.004_bib2","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1038\/srep18751","article-title":"Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming","volume":"6","author":"Xie","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2018.11.004_bib3","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","article-title":"Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis","volume":"25","author":"Hao","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2018.11.004_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.apsb.2016.07.008","article-title":"Fatty liver diseases, bile acids, and FXR","volume":"6","author":"Zhu","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2018.11.004_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","article-title":"Bile acid nuclear receptor FXR and digestive system diseases","volume":"5","author":"Ding","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2018.11.004_bib6","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1016\/j.bmcl.2017.06.003","article-title":"A novel intestinal-restricted FXR agonist","volume":"27","author":"Wang","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2018.11.004_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","article-title":"Farnesoid X receptor modulators 2014\u2013present: a patent review","volume":"28","author":"Sepe","year":"2018","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2018.11.004_bib8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/13543776.2018.1527906","article-title":"FXR modulators for enterohepatic and metabolic diseases","volume":"28","author":"Wang","year":"2018","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2018.11.004_bib9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2018.11.004_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2018.11.004_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2018.11.004_bib12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2018.11.004_bib13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2018.11.004_bib14","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2018.11.004_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2016.12.016","article-title":"Chronic over-expression of fibroblast growth factor 21 increases bile acid biosynthesis by opposing FGF15\/19 action","volume":"15","author":"Zhang","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2018.11.004_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ebiom.2018.08.006","article-title":"Neurotensin contributes to pediatric intestinal failure-associated liver disease via regulating intestinal bile acids uptake","volume":"35","author":"Xiao","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2018.11.004_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ebiom.2017.09.020","article-title":"Microbiota-related changes in bile acid & tryptophan metabolism are associated with gastrointestinal dysfunction in a mouse model of autism","volume":"24","author":"Golubeva","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2018.11.004_bib18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/acs.jproteome.5b00217","article-title":"Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis","volume":"15","author":"Wang","year":"2016","journal-title":"J Proteome Res"},{"key":"10.1016\/j.apsb.2018.11.004_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2893.2012.01628.x","article-title":"Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C","volume":"20","author":"Shlomai","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.apsb.2018.11.004_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2018.10.028","article-title":"Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis","author":"Wang","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2018.11.004_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.apsb.2016.09.003","article-title":"Establishment of a new acute-on-chronic liver failure model","volume":"7","author":"Li","year":"2017","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2018.11.004_bib22","first-page":"1114","article-title":"In vitro tumor necrosis factor cytotoxicity in Hep G2 liver cells","volume":"21","author":"Hill","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2018.11.004_bib23","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1038\/ncomms5573","article-title":"PPAR\u03b1-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis","volume":"5","author":"Zhou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2018.11.004_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1124\/dmd.114.061622","article-title":"Mechanism-based inhibitory and peroxisome proliferator-activated receptor alpha-dependent modulating effects of silybin on principal hepatic drug-metabolizing enzymes","volume":"43","author":"Wang","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2018.11.004_bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hep.21664","article-title":"Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C","volume":"46","author":"Pockros","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2018.11.004_bib26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2016.03.042","article-title":"Targeting the PDGF-B\/PDGFR-\u03b2 interface with destruxin A5 to selectively block PDGF-BB\/PDGFR-\u03b2\u03b2 signaling and attenuate liver fibrosis","volume":"7","author":"Wang","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2018.11.004_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ebiom.2018.01.028","article-title":"IL-4 receptor alpha signaling through macrophages differentially regulates liver fibrosis progression and reversal","volume":"29","author":"Weng","year":"2018","journal-title":"Ebiomedicine"},{"key":"10.1016\/j.apsb.2018.11.004_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.apsb.2017.02.004","article-title":"Advances in ultrasound-targeted microbubble-mediated gene therapy for liver fibrosis","volume":"7","author":"Huang","year":"2017","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2018.11.004_bib29","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1002\/hep.26271","article-title":"Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents","volume":"57","author":"Hatting","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2018.11.004_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2015.11.002","article-title":"Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis","volume":"64","author":"Eguchi","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.apsb.2018.11.004_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hep.24747","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis","volume":"55","author":"Ratziu","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2018.11.004_bib32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jhep.2010.03.016","article-title":"Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis","volume":"53","author":"Anstee","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.apsb.2018.11.004_bib33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/hep.27121","article-title":"E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr-1\/SHP\/EID1 network","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2018.11.004_bib34","first-page":"2286","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology","volume":"59","author":"Verbeke","year":"2014"},{"key":"10.1016\/j.apsb.2018.11.004_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/mol.110.068247","article-title":"Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells","volume":"80","author":"Li","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2018.11.004_bib36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/1389200218666161116120301","article-title":"Immunotherapy in liver diseases: a balance between immunity and tolerance","volume":"17","author":"Mishra","year":"2016","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.apsb.2018.11.004_bib37","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2018.11.004_bib38","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1210\/me.2007-0527","article-title":"Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2018.11.004_bib39","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1600-6143.2006.01595.x","article-title":"Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury","volume":"7","author":"Baskin-Bey","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.apsb.2018.11.004_bib40","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrgastro.2016.143","article-title":"Therapy: obeticholic acid for PBC","volume":"13","author":"Thomas","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383518304143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383518304143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T07:13:28Z","timestamp":1763363608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383518304143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S2211383518304143"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2018.11.004","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2018.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}